Navigation Links
Audentes Therapeutics to Present at the ARM 5th Annual Cell & Gene Therapy Investor Day
Date:4/17/2017

SAN FRANCISCO, April 17, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced that Matthew R. Patterson, President and Chief Executive Officer, will present a corporate overview at the Alliance for Regenerative Medicine's 5th Annual Cell & Gene Therapy Investor Day in Boston, MA.  The presentation is scheduled for Thursday, April 27, 2017, at 9:55 am ET.

To access a live webcast of the presentation, please visit the Events & Presentations page within the Investors & News section of the Audentes website.  Replays of live webcasts will be available on the Audentes website for approximately 30 days following the conference.

About Audentes Therapeutics, Inc.

Audentes Therapeutics (Nasdaq: BOLD) is a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases.  We have four product candidates in development, AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM), AT342 for the treatment of Crigler-Najjar Syndrome, AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).  We are a focused, experienced and passionate team committed to forging strong, global relationships with the patient, research and medical communities.

For more information regarding Audentes, please visit www.audentestx.com.

Audentes Contacts:
Investor Contact:
Thomas Soloway, CFO
415.818.1040
ir@audentestx.com

Media Contact:
Jeffrey Gruis
415.818.1015
media@audentestx.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/audentes-therapeutics-to-present-at-the-arm-5th-annual-cell--gene-therapy-investor-day-300440070.html


'/>"/>
SOURCE Audentes Therapeutics, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Audentes Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
2. Amarantus Forms Subsidiaries "Elto Pharma" to Focus on CNS Disorders and "MANF Therapeutics" to Focus on Ophthalmology
3. Nektar Therapeutics Presents New Preclinical Data for its Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting
4. United Therapeutics Announces Decision From Patent Trial And Appeal Board And Issuance Of New Patents
5. Viking Therapeutics to Present at H.C. Wainwright & Co.s 1st Annual NASH Investor Conference
6. Biotech Stocks on Investors Radar -- Portola Pharma, OvaScience, Ocera Therapeutics, and Ocular Therapeutix
7. Leading Alzheimer’s Expert Joins T3D Therapeutics’ Advisory Board
8. Biotech Stocks Under Scanner -- BioDelivery Sciences, Sage Therapeutics, Benitec Biopharma, and OncoGenex Pharma
9. Oramed to Present at Oligonucleotide and Peptide Therapeutics (OPT) Boston Conference on March 28, 2017
10. FACIT Announces Investment in Propellon Therapeutics
11. Avexegen Therapeutics Announces Exclusive License Agreement with Children’s Hospital Los Angeles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2019)... ... September 17, 2019 , ... Catalent, a global ... Clinical Supplies Management, Asia Pacific (APAC) will present at the upcoming 3rd Annual ... 25-26, 2019. , On Thursday, Sept. 26, at 10:10 a.m., Ms. Delaney will ...
(Date:9/17/2019)... ... September 17, 2019 , ... Jennifer Hermansky ... LLP , have been named to Law360’s 2019 Rising Stars. Hermansky and Xie, named ... 175 attorneys from 1,300 submissions, spanning 39 practice areas. The list highlights attorneys “whose ...
(Date:9/17/2019)... ... 2019 , ... MyBioGate Global Healthcare Innovation Competition Boston Preliminary ... a forum organized by MyBioGate, Inc. and CUBIO Innovation Center that promotes and ... of evaluation, twelve companies out of over 200 applications were selected to compete ...
(Date:9/11/2019)... ... September 10, 2019 , ... ... will educate about the latest developments in genome sequencing analysis. Check your local ... innovation taking place at Rivermap Research & Consulting and will explore its revolutionary ...
Breaking Biology Technology:
(Date:9/30/2019)... ... September 30, 2019 , ... ... increasing the capacity of life science organizations to accelerate innovation and maximize productivity, ... on October 4th. , What: Just 30 days to 21 CFR Part 11 ...
(Date:9/25/2019)... ... September 25, 2019 , ... ... TX, have placed over 20,000 dental implants for a variety of procedures, including ... zygomatic and pterygoid dental implants. Dental implants offer patients permanent tooth ...
(Date:9/24/2019)... (PRWEB) , ... September 23, 2019 , ... ... offices in Cambridge, MA, announce today that Holotype HLA and other Omixon products ... meeting of the American Society for Histocompatibility and Immunogenetics (ASHI) in ...
Breaking Biology News(10 mins):